WO2009082664A3 - Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof - Google Patents

Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof Download PDF

Info

Publication number
WO2009082664A3
WO2009082664A3 PCT/US2008/087375 US2008087375W WO2009082664A3 WO 2009082664 A3 WO2009082664 A3 WO 2009082664A3 US 2008087375 W US2008087375 W US 2008087375W WO 2009082664 A3 WO2009082664 A3 WO 2009082664A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
genetically modified
vesicular stomatitis
compositions
stomatitis virus
Prior art date
Application number
PCT/US2008/087375
Other languages
French (fr)
Other versions
WO2009082664A8 (en
WO2009082664A2 (en
Inventor
Narender Kumar Kaylan
Irina Yurgelonis
Roger Michael Hendry
Mark Cutler
Kristen Elissa Syvertsen
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0821558A priority Critical patent/BRPI0821558A2/en
Priority to AU2008340319A priority patent/AU2008340319A1/en
Priority to JP2010539785A priority patent/JP2011507523A/en
Priority to CN200880127362XA priority patent/CN101981182A/en
Priority to CA2710350A priority patent/CA2710350A1/en
Priority to EP08865185A priority patent/EP2224952A2/en
Application filed by Wyeth filed Critical Wyeth
Priority to KR1020107016259A priority patent/KR20110004354A/en
Publication of WO2009082664A2 publication Critical patent/WO2009082664A2/en
Publication of WO2009082664A8 publication Critical patent/WO2009082664A8/en
Publication of WO2009082664A3 publication Critical patent/WO2009082664A3/en
Priority to IL206462A priority patent/IL206462A0/en
Priority to ZA2010/05182A priority patent/ZA201005182B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/04—Seven-membered rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation
    • C12N2760/20262—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation
    • C12N2760/20264—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to methods for generating genetically modified and attenuated strains of vesicular stomatitis virus (VSV) for use in the preparation of immunogenic compositions. More particularly, the invention relates to the identification of particular genetic modifications of attenuated VSV that result in an increased yield of virus and an increase in stability of the attenuated strains for preparation of the immunogenic compositions. Methods for cell culture propagation and use in large scale production of VSV is also disclosed.
PCT/US2008/087375 2007-12-21 2008-12-18 Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof WO2009082664A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2008340319A AU2008340319A1 (en) 2007-12-21 2008-12-18 Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof
JP2010539785A JP2011507523A (en) 2007-12-21 2008-12-18 Genetically modified attenuated vesicular stomatitis virus, composition and method of use
CN200880127362XA CN101981182A (en) 2007-12-21 2008-12-18 Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use therof
CA2710350A CA2710350A1 (en) 2007-12-21 2008-12-18 Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof
EP08865185A EP2224952A2 (en) 2007-12-21 2008-12-18 Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use therof
BRPI0821558A BRPI0821558A2 (en) 2007-12-21 2008-12-18 genetically modified attenuated vesicular stomatitis virus, ecompositions and methods of use
KR1020107016259A KR20110004354A (en) 2007-12-21 2008-12-18 Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof
IL206462A IL206462A0 (en) 2007-12-21 2010-06-17 Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof
ZA2010/05182A ZA201005182B (en) 2007-12-21 2010-07-20 Genetically modified attenuated vesicular virus,compositions and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1586807P 2007-12-21 2007-12-21
US61/015,868 2007-12-21

Publications (3)

Publication Number Publication Date
WO2009082664A2 WO2009082664A2 (en) 2009-07-02
WO2009082664A8 WO2009082664A8 (en) 2009-09-17
WO2009082664A3 true WO2009082664A3 (en) 2009-11-26

Family

ID=40791563

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/087375 WO2009082664A2 (en) 2007-12-21 2008-12-18 Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof

Country Status (17)

Country Link
US (1) US20090175906A1 (en)
EP (1) EP2224952A2 (en)
JP (1) JP2011507523A (en)
KR (1) KR20110004354A (en)
CN (1) CN101981182A (en)
AR (1) AR069883A1 (en)
AU (1) AU2008340319A1 (en)
BR (1) BRPI0821558A2 (en)
CA (1) CA2710350A1 (en)
CL (1) CL2008003794A1 (en)
CO (1) CO6290704A2 (en)
IL (1) IL206462A0 (en)
PE (1) PE20091104A1 (en)
RU (1) RU2010124788A (en)
TW (1) TW200932259A (en)
WO (1) WO2009082664A2 (en)
ZA (1) ZA201005182B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010080909A1 (en) * 2009-01-08 2010-07-15 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
US20120171246A1 (en) 2009-09-10 2012-07-05 Yale University Immunization to reduce neurotoxicity during treatment with cytolytic viruses
WO2011056993A1 (en) 2009-11-04 2011-05-12 Yale University Compositions and methods for treating cancer with attenuated oncolytic viruses
KR20120068647A (en) * 2010-12-18 2012-06-27 아이진 주식회사 Vaccines capable of inducing enhanced immune responses
WO2012170814A1 (en) * 2011-06-08 2012-12-13 The Ohio State University Norovirus immunogens and related materials and methods
WO2015077714A1 (en) 2013-11-22 2015-05-28 Yale University Chimeric vsv virus compositions and methods of use thereof for treatment of cancer
GB201614050D0 (en) 2016-08-17 2016-09-28 Glaxosmithkline Ip Dev Ltd Method for purifying viral vectors
US11130956B2 (en) * 2017-06-05 2021-09-28 Arizona Board Of Regents On Behalf Of Arizona State University Reducing the toxicity of agrobacterium endotoxin
MX2020004836A (en) * 2017-11-06 2020-10-16 Rapt Therapeutics Inc Chemokine receptor modulators for treatment of epstein barr virus positive cancer.
CN110317832B (en) * 2018-03-28 2022-07-05 西比曼生物科技（香港）有限公司 GMP (good manufacturing practice) scale preparation method of purified preparation of recombinant lentiviral vector
CN110317791A (en) 2018-03-29 2019-10-11 西比曼生物科技（香港）有限公司 The method of GMP grades of serum free suspension cell large-scale production slow virus
CN110577585A (en) * 2018-06-07 2019-12-17 中国医学科学院基础医学研究所 Vesicular stomatitis virus envelope glycoprotein variant, and construction method and application thereof
WO2020018705A1 (en) 2018-07-17 2020-01-23 Yale University Methods for treatment of cancer using chikungunya-vsv chimeric virus
WO2020029274A1 (en) * 2018-08-10 2020-02-13 苏州奥特铭医药科技有限公司 Preparation method for attenuated baculovirus and application thereof
CN110305850A (en) * 2019-05-15 2019-10-08 苏州奥特铭医药科技有限公司 A method of oncolytic virus is prepared using 293 cell productions
CR20220606A (en) * 2020-06-03 2023-01-23 Boehringer Ingelheim Int Recombinant rhabdovirus encoding for a cd80 extracellular domain fc-fusion protein
WO2022092779A1 (en) * 2020-10-29 2022-05-05 에스케이바이오사이언스 주식회사 Viral vector comprising sars-coronavirus-2 antigen material and use of same
CN116144608A (en) * 2021-09-29 2023-05-23 上海行深生物科技有限公司 Virus culture method
CN117065052A (en) * 2022-05-16 2023-11-17 上海行深生物科技有限公司 Methods of delivering self-replicating RNA molecules
CN115725657B (en) * 2022-09-16 2024-06-04 中国科学院广州生物医药与健康研究院 Segmented vesicular stomatitis virus vector and preparation method and application thereof
CN115948352A (en) * 2022-11-29 2023-04-11 浙江迪福润丝生物科技有限公司 Weakening method of vesicular stomatitis virus, weakening virus strain and application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019380A2 (en) * 1999-09-17 2001-03-22 Pro-Virus, Inc. Oncolytic virus

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138854B1 (en) * 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
SE8405493D0 (en) * 1984-11-01 1984-11-01 Bror Morein IMMUNOGENT COMPLEX AND KITCHEN FOR PREPARING IT AND USING IT AS IMMUNOSTIMENTING AGENTS
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
PT702085E (en) * 1994-07-18 2004-04-30 Karl Klaus Conzelmann NON-SEGMENTED CHEMICAL RNA VIRUS INFECTIOUS RECOMBINANT
US7153510B1 (en) * 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US6596529B1 (en) * 1997-05-02 2003-07-22 Uab Research Foundation Manipulation of negative stranded RNA viruses by rearrangement of their genes and uses thereof
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6673572B2 (en) * 1998-06-03 2004-01-06 Wyeth Holdings Corporation Methods for rescue of RNA viruses
BRPI0411247A (en) * 2003-06-09 2006-07-25 Wyeth Corp improved process for recovering non-segmented negative filament rna viruses from cdna
MX343109B (en) * 2004-04-09 2016-10-25 Wyeth * Synergistic attenutation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof.
BRPI0710820A2 (en) * 2006-04-20 2011-08-23 Wyeth Corp process for purifying the vesicular stomatitis virus (vsv) from the cell culture fluid of a vsv infected mammalian cell culture; vsv purified according to the process; pharmaceutical composition; and immunogenic composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019380A2 (en) * 1999-09-17 2001-03-22 Pro-Virus, Inc. Oncolytic virus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEVIN J M ET AL: "An algorithm for secondary structure determination in proteins based on sequence similarity", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 205, no. 2, 15 September 1986 (1986-09-15), pages 303 - 308, XP025607061, ISSN: 0014-5793, [retrieved on 19860915] *

Also Published As

Publication number Publication date
PE20091104A1 (en) 2009-07-18
TW200932259A (en) 2009-08-01
EP2224952A2 (en) 2010-09-08
IL206462A0 (en) 2010-12-30
CA2710350A1 (en) 2009-07-02
RU2010124788A (en) 2012-01-27
AU2008340319A1 (en) 2009-07-02
AR069883A1 (en) 2010-02-24
US20090175906A1 (en) 2009-07-09
WO2009082664A8 (en) 2009-09-17
CL2008003794A1 (en) 2009-03-20
CN101981182A (en) 2011-02-23
KR20110004354A (en) 2011-01-13
JP2011507523A (en) 2011-03-10
CO6290704A2 (en) 2011-06-20
BRPI0821558A2 (en) 2015-11-03
WO2009082664A2 (en) 2009-07-02
ZA201005182B (en) 2011-05-25

Similar Documents

Publication Publication Date Title
WO2009082664A8 (en) Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof
WO2021155243A8 (en) Respiratory virus immunizing compositions
MX2022009280A (en) Coronavirus rna vaccines.
WO2022221359A8 (en) Epstein-barr virus mrna vaccines
WO2007002008A3 (en) Methods and compositions for expressing negative-sense viral rna in canine cells
AU2007240448A8 (en) Methods and compositions for expressing negative-sense viral RNA in canine cells
TN2011000628A1 (en) Production of polio virus at high titres for vaccine production
MX2010000525A (en) Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant.
WO2005042728A3 (en) Immortalized avian cell lines for virus production
BRPI0714495B8 (en) Deficient lentivirus for pseudotyped recombinant replication
WO2011159684A3 (en) Generation of induced pluripotent stem cells from small volumes of peripheral blood
WO2007136428A8 (en) Nutraceutical compositions from microalgae and related methods of production and administration
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
WO2009080743A3 (en) Plants with increased yield (ko nue)
WO2012083445A8 (en) Virus like particle production in plants
WO2009099877A3 (en) Closterovirus vectors and methods
IN2012DN03209A (en)
WO2008129971A1 (en) Improved persistently infective sendai virus vector
WO2012047679A8 (en) Consensus antigen constructs and vaccines made therefrom, and methods of using same to treat malaria
WO2005115448A8 (en) Multi plasmid system for the production of influenza virus
MX2018006627A (en) Increasing virus-like particle yield in plants.
IN2015DN03206A (en)
PH12020552252A1 (en) Influenza virus hemagglutinin mutants
MX2010005701A (en) Method for producing vaccinal viral strain of a virus of the reoviridae family.
WO2010008576A3 (en) Idna vaccines and methods for using the same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880127362.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08865185

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 586239

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 12010501425

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2710350

Country of ref document: CA

Ref document number: 10074482

Country of ref document: CO

Ref document number: 4488/DELNP/2010

Country of ref document: IN

Ref document number: 2010539785

Country of ref document: JP

Ref document number: MX/A/2010/007018

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008340319

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008865185

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008340319

Country of ref document: AU

Date of ref document: 20081218

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107016259

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010124788

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: PI 2010002889

Country of ref document: MY

ENP Entry into the national phase

Ref document number: PI0821558

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100621